Transdermal estradiol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of menopausal complaints
- PMID: 2083514
- DOI: 10.2165/00003495-199040040-00006
Transdermal estradiol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of menopausal complaints
Abstract
The estradiol transdermal therapeutic system is a cutaneous delivery device which delivers estradiol into the systemic circulation via the stratum corneum at a constant rate for up to 4 days. Physiological levels of estradiol (the major estrogen secreted by the ovaries in premenopausal women) can therefore be maintained in postmenopausal women with low daily doses because first-pass hepatic metabolism is avoided. In short term clinical studies, the beneficial effects of transdermal estradiol on plasma gonadotrophins, maturation of the vaginal epithelium, metabolic parameters of bone resorption and menopausal symptoms (hot flushes, sleep disturbance, genitourinary discomfort and mood alteration) appear to be comparable to those of oral and subcutaneous estrogens, while the undesirable effects of oral estrogens on hepatic metabolism are avoided. As with oral or injectable estrogen replacement therapy, concomitant sequential progestagen is recommended for patients with an intact uterus during transdermal estradiol administration, in order to reduce endometrial stimulation. Transdermal estradiol has been well tolerated in clinical trials, with local irritation at the site of application being the most common adverse effect. The incidence of systemic estrogenic effects appears to be comparable to that observed with oral therapy. Thus, transdermal estradiol offers near-physiological estrogen replacement in postmenopausal women in a convenient low-dose form which may avoid some of the complications of higher dose oral therapy. Long term epidemiological studies are warranted to determine whether transdermal estradiol therapy provides protection against osteoporosis and fractures and cardiovascular disease equivalent to that offered by oral and injectable estrogens. However, despite the importance of such data, it seems reasonable to conclude at this stage of its development that transdermal estradiol represents an important advance in hormone replacement therapy.
Similar articles
-
Transdermal estradiol. A review of its pharmacological profile, and therapeutic potential in the prevention of postmenopausal osteoporosis.Drugs Aging. 1992 Nov-Dec;2(6):487-507. doi: 10.2165/00002512-199202060-00005. Drugs Aging. 1992. PMID: 1493353 Review.
-
Transdermal estradiol/norethisterone. A review of its pharmacological properties and clinical use in postmenopausal women.Drugs Aging. 1994 Mar;4(3):238-56. doi: 10.2165/00002512-199404030-00006. Drugs Aging. 1994. PMID: 8199397 Review.
-
Nanoparticle delivery for transdermal HRT.Nanomedicine. 2012 Sep;8 Suppl 1:S83-9. doi: 10.1016/j.nano.2012.05.008. Epub 2012 May 26. Nanomedicine. 2012. PMID: 22640909 Review.
-
A comparative study of the effects of an estradiol-releasing vaginal ring combined with an oral gestagen versus transdermal estrogen combined with a levonorgestrel-releasing IUD: clinical findings and endometrial response.Int J Fertil Menopausal Stud. 1996 Nov-Dec;41(6):522-7. Int J Fertil Menopausal Stud. 1996. PMID: 9010746 Clinical Trial.
-
Comparison of steady state development and reduction of menopausal symptoms after oral or transdermal delivery of 17-β-estradiol in young healthy symptomatic menopausal women.Horm Mol Biol Clin Investig. 2014 Jun;18(3):123-36. doi: 10.1515/hmbci-2013-0047. Horm Mol Biol Clin Investig. 2014. PMID: 25390008
Cited by
-
Effects of hormonal replacement therapy on plasma sex hormone-binding globulin, androgen and insulin-like growth factor-1 levels in postmenopausal women.J Endocrinol Invest. 1996 Sep;19(8):535-41. doi: 10.1007/BF03349013. J Endocrinol Invest. 1996. PMID: 8905477
-
The range and variation in serum estradiol concentration in perimenopausal and postmenopausal women treated with transdermal estradiol in a real-world setting: a cross-sectional study.Menopause. 2025 Feb 1;32(2):103-111. doi: 10.1097/GME.0000000000002459. Epub 2024 Dec 17. Menopause. 2025. PMID: 39689249 Free PMC article.
-
Drug-Drug Interaction Studies of Elagolix with Oral and Transdermal Low-Dose Hormonal Add-Back Therapy.Clin Pharmacokinet. 2021 Jan;60(1):133-143. doi: 10.1007/s40262-020-00921-y. Clin Pharmacokinet. 2021. PMID: 32696440
-
The Design Features, Quality by Design Approach, Characterization, Therapeutic Applications, and Clinical Considerations of Transdermal Drug Delivery Systems-A Comprehensive Review.Pharmaceuticals (Basel). 2024 Oct 9;17(10):1346. doi: 10.3390/ph17101346. Pharmaceuticals (Basel). 2024. PMID: 39458987 Free PMC article. Review.
-
Estrogen formulations and beauty care practices in Japanese women.Int J Womens Health. 2012;4:19-24. doi: 10.2147/IJWH.S28368. Epub 2012 Jan 31. Int J Womens Health. 2012. PMID: 22312196 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials